{"gene":"TRAF3IP2","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":2000,"finding":"Act1/CIKS was identified as a novel protein that directly interacts with NEMO/IKKγ in cells. When ectopically expressed, CIKS stimulates IKK and SAPK/JNK kinases and transactivates an NF-κB-dependent reporter, with NF-κB activation prevented by kinase-deficient IKK mutants.","method":"Co-immunoprecipitation, ectopic expression, NF-κB reporter assay, dominant-negative kinase mutants","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent papers (PMID 10962024 and 10962033) published simultaneously identified the same protein by different labs using reciprocal co-IP and functional reporter assays","pmids":["10962033","10962024"],"is_preprint":false},{"year":2000,"finding":"Act1 associates with and activates IκB kinase (IKK), leading to liberation of NF-κB from its IκB complex, and also activates JNK. Act1 failed to activate NF-κB in an IL-1-unresponsive mutant cell line despite all known signaling components being present, suggesting interaction with an unknown component of IL-1 signaling.","method":"Co-immunoprecipitation, NF-κB reporter assay, JNK kinase assay, IL-1-unresponsive mutant cell line","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP and functional assays in a defined genetic background, replicated across two simultaneous papers","pmids":["10962024"],"is_preprint":false},{"year":2002,"finding":"Act1 interacts with TRAF6 specifically (not other TRAF family members) via its amino-terminal half, and Act1-mediated NF-κB activation is inhibited by a dominant-negative TRAF6 mutant in a dose-dependent manner, placing TRAF6 downstream of Act1 in IL-1/Toll-mediated signaling.","method":"Co-immunoprecipitation, dominant-negative TRAF6, NF-κB reporter assay","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP with domain mapping and dominant-negative epistasis, single lab","pmids":["12459498"],"is_preprint":false},{"year":2002,"finding":"Endogenous Act1 is recruited to the CD40 receptor in epithelial cells upon CD40L stimulation, and Act1 interacts with TRAF3 (a CD40-associated component). Transfection of Act1 into Act1-negative cervical epithelial cells renders them sensitive to CD40L-induced NF-κB activation and protects them from CD40L-induced apoptosis.","method":"Co-immunoprecipitation of endogenous proteins, ectopic expression rescue, NF-κB reporter assay, apoptosis assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — endogenous Co-IP and functional rescue experiments, single lab","pmids":["12089335"],"is_preprint":false},{"year":2003,"finding":"CIKS/Act1 forms homo-oligomers, interacts with NEMO/IKKγ, and is recruited to the IKK complex upon cell stimulation. A deletion mutant that retains oligomerization and NEMO binding but lacks a second domain fails to activate NF-κB, indicating that recruitment to IKK is necessary but not sufficient for NF-κB activation.","method":"Co-immunoprecipitation, deletion mutagenesis, NF-κB reporter assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain deletion mutagenesis with functional readout, single lab","pmids":["12943667"],"is_preprint":false},{"year":2004,"finding":"Act1 functions as a negative regulator of CD40- and BAFF-mediated B cell survival. Act1 deficiency leads to stronger IκB phosphorylation, processing of NF-κB2 (p100/p52), and activation of JNK, ERK, and p38 pathways in B cells. The phenotype is largely blocked in CD40-Act1 and BAFF-Act1 double-knockout mice, genetically placing Act1 downstream of CD40 and BAFFR.","method":"Genetic knockout, double-knockout epistasis, signaling pathway analysis by immunoblot","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with double-KO epistasis and defined signaling phenotype, multiple orthogonal readouts","pmids":["15485634"],"is_preprint":false},{"year":2006,"finding":"Act1 directly associates with IL-17 receptor (IL-17RA) likely via homotypic SEFIR domain interaction and acts as a membrane-proximal adaptor. Deficiency of Act1 in fibroblasts abrogates IL-17-induced cytokine and chemokine expression, C/EBPβ, C/EBPδ, and IκBζ induction, and NF-κB pathway activation.","method":"Co-immunoprecipitation, Act1-deficient fibroblasts, immunoblot/qPCR for downstream targets","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct physical interaction and loss-of-function in primary cells with multiple orthogonal readouts, replicated in subsequent papers","pmids":["17035243"],"is_preprint":false},{"year":2007,"finding":"Act1 is essential for IL-17 receptor (IL-17R) signaling in vivo. After IL-17 stimulation, Act1 is recruited to IL-17R via SEFIR domain interaction, followed by recruitment of TAK1 and TRAF6 to mediate NF-κB activation. Act1-deficient primary astroglial and gut epithelial cells showed abolished IL-17-induced inflammatory gene expression, and Act1-deficient mice showed reduced EAE and DSS-induced colitis.","method":"Genetic knockout mouse, primary cell studies, co-immunoprecipitation, SEFIR domain analysis, in vivo disease models","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with defined in vivo phenotypes, co-IP defining the receptor complex, replicated across multiple disease models and cell types","pmids":["17277779"],"is_preprint":false},{"year":2007,"finding":"Two independent signaling pathways are required for IL-17A-induced gene expression in human airway epithelial cells: (1) a JAK1-associated PI3K signaling axis independent of NF-κB, and (2) an Act1/TRAF6/TAK1-mediated NF-κB activation pathway. siRNA knockdown of Act1, TRAF6, or TAK1 reduced IL-17A-inducible gene expression and NF-κB activation.","method":"siRNA knockdown, PI3K inhibitor, JAK inhibitor, NF-κB DNA-binding assay, promoter activity assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with functional readouts, multiple inhibitors, single lab","pmids":["17982039"],"is_preprint":false},{"year":2009,"finding":"Act1 is a U-box E3 ubiquitin ligase. Using the Ubc13-Uev1A E2 complex, Act1 mediates Lys63-linked ubiquitination of TRAF6, and this activity is essential for IL-17-mediated NF-κB signaling. Deletion and point mutations of the Act1 U-box abolished TRAF6 ubiquitination and impaired IL-17-dependent signaling and gene expression in Act1-/- MEFs. Lys-124 of TRAF6 was identified as a critical ubiquitination site.","method":"In vitro ubiquitination assay, U-box point mutagenesis, rescue of Act1-/- MEFs, immunoblot for K63-linked ubiquitin chains, site-directed mutagenesis of TRAF6-K124","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro ubiquitination reconstitution with mutagenesis of both enzyme (U-box) and substrate (K124), validated in primary cells","pmids":["19825828"],"is_preprint":false},{"year":2009,"finding":"Act1 is an essential signaling molecule for IL-25 (IL-17E) receptor signaling in addition to IL-17 receptor signaling. Act1 deficiency abolished IL-25-induced expression of IL-4, IL-5, IL-13, eotaxin-1, and pulmonary eosinophilia in mice.","method":"Act1-deficient mice, cytokine/chemokine expression assays, pulmonary inflammation model","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with defined in vivo phenotype, replicated by two independent labs in same issue","pmids":["19155512","19155511"],"is_preprint":false},{"year":2010,"finding":"Act1 deficiency specifically in neuroectoderm-derived CNS-resident cells (neurons, astrocytes, oligodendrocytes) markedly reduced EAE severity. Act1-deficient astrocytes showed impaired IL-17-mediated inflammatory gene induction, identifying astrocytes as critical cellular targets of IL-17-Act1 signaling in CNS inflammation.","method":"Conditional cell-type-specific Act1 knockout mice, EAE model, gene expression analysis in primary astrocytes","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional cell-type-specific KO with defined in vivo phenotype and in vitro mechanistic confirmation","pmids":["20303295"],"is_preprint":false},{"year":2011,"finding":"CIKS/Act1 is essential for all IL-17-induced immediate-early genes in primary mouse embryo fibroblasts. A novel N-terminal subdomain of CIKS is both necessary and sufficient for interaction with TRAF6 and for IL-17-mediated NF-κB activation.","method":"CIKS-deficient MEFs, domain deletion mutagenesis, Co-IP, NF-κB reporter assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain mapping with functional readouts in primary cells, single lab","pmids":["21335551"],"is_preprint":false},{"year":2011,"finding":"Persistent IL-17 stimulation leads to Lys48-linked polyubiquitination and degradation of Act1 in a phosphorylation-dependent manner via SCFβ-TrCP E3 ligase complexes (containing β-TrCP1 or β-TrCP2), desensitizing IL-17R signaling. Dominant-negative β-TrCP or knockdown of β-TrCP1/2 markedly reduced IL-17-induced Act1 ubiquitination and degradation.","method":"Co-immunoprecipitation of Act1 with β-TrCP, dominant-negative β-TrCP, siRNA knockdown, ubiquitin linkage analysis","journal":"Science signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, dominant-negative, and siRNA approaches converge, single lab","pmids":["22045853"],"is_preprint":false},{"year":2011,"finding":"The CC' loop of the Act1 SEFIR domain (not the BB' loop as in TIR domains) is required for heterotypic interaction with IL-17RA SEFIR domain. Deletion of the CC' loop from Act1 or IL-17RA abolished the Act1-IL-17RA interaction. Surface plasmon resonance confirmed direct binding of a CC' loop peptide to IL-17RA. A cell-permeable CC' loop decoy peptide inhibited IL-17- and IL-25-mediated signaling in vitro and in vivo.","method":"Co-immunoprecipitation, SEFIR domain deletion mutagenesis, surface plasmon resonance, cell-permeable peptide inhibition in vitro and in vivo","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct binding measured by SPR, mutagenesis of both interacting proteins, and in vivo validation with decoy peptide","pmids":["22045852"],"is_preprint":false},{"year":2012,"finding":"Act1 is recruited to CD40 and BAFFR indirectly via TRAF3 through a TRAF-binding site in Act1, whereas Act1 interacts with IL-17R through its C-terminal SEFIR domain. These distinct domain requirements underlie the opposing roles of Act1 in B cell vs. T cell signaling.","method":"Domain interaction analysis, genetic knockout, double-knockout epistasis","journal":"Cytokine / Advances in experimental medicine and biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain-level interactions established by Co-IP and genetic approaches, reviewed/consolidated evidence","pmids":["18061473","21948371"],"is_preprint":false},{"year":2012,"finding":"Act1 is a client protein of the molecular chaperone Hsp90. The psoriasis-associated D10N variant of Act1 is defective in its interaction with Hsp90, resulting in global loss of Act1 function. Act1-deficient mice develop spontaneous IL-22-dependent skin inflammation, revealing that loss of Act1 function in IL-17 signaling leads to hyperactive Th17 responses.","method":"Co-immunoprecipitation of Act1-Hsp90, Act1-deficient mice, conditional knockout, cytokine/antibody neutralization in vivo","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP, genetic KO, in vivo disease model, and mechanistic connection to psoriasis variant, multiple orthogonal methods","pmids":["23202271"],"is_preprint":false},{"year":2012,"finding":"TBK1 directly phosphorylates Act1 on three serine sites to suppress IL-17R-mediated NF-κB activation. IKKi also phosphorylates Act1 on the same sites redundantly. Phosphorylation of these sites inhibits Act1 association with TRAF6 and consequently NF-κB activation. TRAF6 (not TRAF3) is critical for IL-17-induced TBK1 activation, its association with Act1, and subsequent Act1 phosphorylation.","method":"In vitro kinase assay, site-directed mutagenesis, co-immunoprecipitation, siRNA knockdown, immunoblot for phosphorylation","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay with site mutagenesis combined with co-IP and genetic knockdown to place TBK1 in the pathway","pmids":["22851696"],"is_preprint":false},{"year":2012,"finding":"Act1 mediates IL-17-induced EAE pathogenesis selectively in NG2+ glial cells, not in neurons or mature oligodendrocytes. Deletion of Act1 in NG2+ glia resulted in markedly reduced EAE severity. IL-17 exhibited inhibitory effects on maturation and survival of oligodendrocyte lineage cells.","method":"Conditional cell-type-specific Act1 knockout mice (NG2-Cre, GFAP-Cre, Olig1-Cre, Syn1-Cre), EAE model, in vitro oligodendrocyte differentiation assays","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple conditional KO lines with defined cellular specificity and in vivo phenotype","pmids":["23995070"],"is_preprint":false},{"year":2013,"finding":"A biallelic missense mutation (T536I) in ACT1, located in the SEFIR domain, abolished the homotypic interaction of ACT1 with IL-17 receptors (but not homodimerization), resulting in failure to respond to IL-17A, IL-17F, and IL-17E in patient fibroblasts and T cells. In contrast, the D10N variant in the TRAF-interacting domain impairs but does not abolish IL-17 responses.","method":"Patient-derived fibroblasts, Co-IP of mutant ACT1 with IL-17R, cytokine response assays, comparison of SEFIR vs. TRAF-domain mutations","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — natural human mutation with loss-of-function validated in patient cells with mechanistic domain localization confirmed by Co-IP","pmids":["24120361"],"is_preprint":false},{"year":2013,"finding":"HuR is required for IL-17-induced Act1-mediated CXCL1/CXCL5 mRNA stabilization. Act1-mediated polyubiquitination of HuR is required for HuR binding to CXCL1 mRNA, leading to mRNA stabilization. IL-17 induces co-shift of Act1 and HuR to polysomal fractions; HuR deficiency reduces translation-active chemokine mRNAs.","method":"HuR knockout in distal lung epithelium, Co-IP of Act1-HuR, sucrose gradient fractionation, mRNA decay assay, in vivo neutrophilia model","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO combined with biochemical Co-IP and polysome profiling, in vivo validation","pmids":["23772036"],"is_preprint":false},{"year":2013,"finding":"Chlamydia pneumoniae inclusion membrane protein CP0236 interacts with Act1 in HeLa cells. C. pneumoniae infection causes Act1 to associate with the chlamydial inclusion membrane, sequestering it away from the IL-17 receptor, thereby inhibiting NF-κB activation in IL-17-stimulated infected cells.","method":"Yeast two-hybrid screen, co-immunoprecipitation of CP0236 with endogenous Act1, immunofluorescence localization","journal":"Cellular microbiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid confirmed by co-IP, localization study with functional consequence, single lab","pmids":["19159390"],"is_preprint":false},{"year":2014,"finding":"The crystal structure of the IL-17RA SEFIR domain at 2.3 Å resolution reveals that helix αC is critical for interaction with Act1 and IL-17-stimulated gene expression. The CC' loop region and helix αC form a composite ligand-binding surface for recruiting Act1, defining the structural basis for SEFIR-SEFIR interaction specificity.","method":"X-ray crystallography (2.3 Å resolution), structure-based mutagenesis, gene expression assays","journal":"Acta crystallographica. Section D, Biological crystallography","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with functional validation by mutagenesis of critical interaction helix","pmids":["24816115"],"is_preprint":false},{"year":2014,"finding":"The psoriasis-associated D10N variant of ACT1 shows reduced binding to TRAF6, suggesting altered modulation of immunoregulatory signals through TRAF interactions. Functional assays demonstrated this impaired binding is associated with reduced IL-17 signaling activity.","method":"Functional binding assay, variant protein expression, comparison of wild-type vs. D10N variant interaction with TRAF6","journal":"Nature genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional binding assay with disease-associated variant, replicated in subsequent studies","pmids":["20953186"],"is_preprint":false},{"year":2014,"finding":"Syk kinase is recruited to the IL-17R signaling complex (with TRAF6 and Act1) upon IL-17A stimulation. Syk acts upstream of TAK1. Syk siRNA or pharmacological inhibition diminished TRAF6-Act1 interaction and TRAF6 K63-polyubiquitination, placing Syk as an upstream regulator of Act1-TRAF6 interaction in IL-17 signaling.","method":"Co-immunoprecipitation, siRNA knockdown, kinase inhibitor, TRAF6 ubiquitination assay, CCL20 promoter activity","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and siRNA with functional ubiquitination readout, single lab","pmids":["25202827"],"is_preprint":false},{"year":2014,"finding":"ACT1 has two human isoforms (D10N and D19N) due to alternative splicing. Both are Hsp90 client proteins, but ACT1-D19N has an additional 9 amino acids providing a second Hsp90 binding site absent in ACT1-D10N. ACT1-D10N is a non-functional dead protein for IL-17 signaling, whereas ACT1-D19N is fully responsive. The two isoforms are differentially expressed in fibroblasts vs. T cells.","method":"Hsp90 co-IP with isoform-specific constructs, IL-17 signaling functional assay, isoform expression analysis in primary cells","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP domain mapping with functional assays in primary cells, single lab","pmids":["25024377"],"is_preprint":false},{"year":2015,"finding":"IL-17-induced CIKS/Act1 interaction with the DEAD box protein DDX3X (requiring the DDX3X helicase domain but not its ATPase activity) controls the stability of Zc3h12a mRNA. DDX3X knockdown decreases IL-17-induced Zc3h12a mRNA stability without affecting other mRNAs. IKKε, TRAF2, and TRAF5 are also required for this stabilization.","method":"Co-immunoprecipitation of CIKS-DDX3X, DDX3X knockdown, mRNA stability assay, RIP (RNA immunoprecipitation)","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain requirement and RNA-binding confirmation, single lab","pmids":["25710910"],"is_preprint":false},{"year":2018,"finding":"Act1 binds and stabilizes mRNAs encoding key inflammatory proteins via its SEFIR domain binding to a stem-loop structure (SEFIR-binding element, SBE) in the 3' UTR of Cxcl1 mRNA. mRNA-bound Act1 directs formation of three compartmentally distinct RNA-protein complexes (RNPs) that regulate: (1) preventing mRNA decay in the nucleus, (2) inhibiting mRNA decapping in P-bodies, and (3) promoting translation. SBE RNA aptamers decreased IL-17-mediated mRNA stabilization and inflammation in vivo.","method":"RNA immunoprecipitation, SEFIR domain mutagenesis, sucrose gradient polysome fractionation, P-body imaging, SBE aptamer inhibition in vitro and in vivo mouse models","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal biochemical methods (RIP, RNA structure, polysome profiling, P-body imaging) plus in vivo therapeutic validation with aptamers","pmids":["29563620"],"is_preprint":false},{"year":2018,"finding":"Act1 functions as a negative regulator in T and B cells via direct inhibition of STAT3. Mass spectrometry identified an Act1-STAT3 complex. Act1 deficiency (but not IL-17RA/RC/RB deficiency) results in hyperactivated IL-23- and IL-21-induced STAT3 activation in T and B cells, respectively, causing SLE- and Sjögren's-like diseases.","method":"Mass spectrometry identification of Act1-STAT3 complex, co-immunoprecipitation, conditional KO comparison (Act1 vs. IL-17R subunits), STAT3 phosphorylation assay, in vivo disease model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — MS identification of complex confirmed by Co-IP, genetic comparison of multiple KO lines defines STAT3 as Act1-specific target independent of IL-17R","pmids":["30013031"],"is_preprint":false},{"year":2021,"finding":"The FYN-TRAF3IP2 gene fusion (identified in peripheral T-cell lymphoma) leads to aberrant NF-κB signaling downstream of T cell receptor activation. FYN-TRAF3IP2 expression in hematopoietic progenitors induces NF-κB-driven T cell transformation in mice and cooperates with Tet2 loss. IκB kinase inhibitors delivered anti-lymphoma effects in vitro and in vivo.","method":"RNA-sequencing identification of fusion, mouse hematopoietic progenitor transformation assay, NF-κB signaling analysis, IKK inhibitor treatment in vitro and in vivo","journal":"Nature cancer","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo transformation assay with genetic epistasis (Tet2 cooperation) and pharmacological validation with IKK inhibitors, replicated in independent cohort","pmids":["33928261"],"is_preprint":false},{"year":2012,"finding":"CIKS/Act1 binds to IKK and JNK under basal conditions (functioning as a scaffold), and this association is enhanced by Angiotensin-II stimulation. CIKS-null cardiomyocytes lack Ang-II-induced IKK/NF-κB and JNK/AP-1 activation, IL-18 and MMP-9 induction, and hypertrophy both in vitro and in vivo, demonstrating CIKS is required for Ang-II-induced cardiac hypertrophy.","method":"Co-immunoprecipitation (CIKS/IKK/JNK), CIKS-null mice, Ang-II infusion model, cardiac function measurements","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP scaffold function and genetic KO with in vivo disease model, single lab","pmids":["22575763"],"is_preprint":false},{"year":2022,"finding":"IL-17A stimulates the recruitment of MST1 to ACT1 in keratinocytes, which leads to reduced MST1-LATS1 interaction and YAP dephosphorylation (activation), promoting AREG expression and keratinocyte proliferation.","method":"Co-immunoprecipitation of ACT1-MST1, YAP phosphorylation immunoblot, keratinocyte proliferation assay","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and downstream phosphorylation assays establishing a new ACT1-MST1-YAP axis, single lab","pmids":["35304250"],"is_preprint":false},{"year":2011,"finding":"A novel amino-terminal motif of Act1 is critical for binding to TRAF6 and activating NF-κB-dependent gene expression, conserved throughout vertebrate evolution. Zebrafish Act1 (lacking the helix-loop-helix and Ufd2-box domains present in higher vertebrates) cannot induce JNK phosphorylation or activate cytokine expression in human cells, but can still bind TRAF6 and activate NF-κB.","method":"Evolutionary sequence analysis, domain truncation, co-immunoprecipitation of zebrafish Act1 with human TRAF6, NF-κB reporter assay, JNK phosphorylation assay","journal":"Journal of molecular evolution","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain functional analysis using orthologs with co-IP and reporter assays, single lab","pmids":["21643828"],"is_preprint":false},{"year":2019,"finding":"Diabetes-induced retinal endothelial cell death occurs through an IL-17A/IL-17R → Act1/FADD signaling cascade causing caspase-mediated apoptosis. Act1 was shown to interact with FADD, identifying Act1 as a bridge between the IL-17 receptor complex and the apoptotic FADD/caspase pathway.","method":"IL-17A-/- mouse STZ diabetes model, retinal endothelial cell ex vivo studies, Act1/FADD signaling pathway analysis, capillary degeneration quantification","journal":"Journal of diabetes and its complications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KO model with ex vivo mechanistic pathway tracing, single lab","pmids":["31239234"],"is_preprint":false}],"current_model":"TRAF3IP2/Act1 is a multifunctional cytoplasmic adaptor and U-box E3 ubiquitin ligase that serves as the essential membrane-proximal signal transducer for the IL-17 receptor family: upon IL-17 stimulation, Act1 is recruited to IL-17RA via heterotypic CC'-loop-mediated SEFIR domain interaction, where it catalyzes Lys63-linked ubiquitination of TRAF6 (via Ubc13-Uev1A) to activate IKK/NF-κB and JNK/AP-1, stabilizes inflammatory mRNAs by binding SEFIR-binding elements in their 3'-UTRs to assemble nucleus/P-body/polysome RNP complexes, and can be negatively regulated by TBK1/IKKi-mediated phosphorylation that disrupts Act1-TRAF6 interaction or by SCFβ-TrCP-mediated Lys48-linked degradation; independently of IL-17 signaling, Act1 acts as a negative regulator in B cells (attenuating CD40/BAFF-mediated survival via TRAF3) and in T/B cells (directly inhibiting STAT3), and the oncogenic FYN-TRAF3IP2 fusion drives NF-κB-dependent T cell lymphoma downstream of TCR activation."},"narrative":{"mechanistic_narrative":"TRAF3IP2 (Act1/CIKS) is the essential membrane-proximal adaptor and signal transducer of the IL-17 receptor family, coupling IL-17/IL-25 receptor engagement to inflammatory gene expression in fibroblasts, epithelial cells, astrocytes, and CNS glia [PMID:17035243, PMID:17277779, PMID:19155512, PMID:19155511, PMID:20303295, PMID:23995070]. Upon IL-17 stimulation, Act1 is recruited to IL-17RA through a heterotypic SEFIR-SEFIR interaction in which the Act1 CC' loop engages a composite surface formed by the IL-17RA CC' loop and helix αC [PMID:22045852, PMID:24816115], and it then recruits TRAF6 and TAK1 to activate IKK/NF-κB and JNK/AP-1 [PMID:10962024, PMID:12459498, PMID:17277779]. Act1 itself is a U-box E3 ubiquitin ligase that, with the Ubc13-Uev1A E2, catalyzes Lys63-linked ubiquitination of TRAF6 at Lys-124, an activity required for downstream NF-κB signaling [PMID:19825828]. Beyond transcriptional activation, Act1 binds a SEFIR-binding element stem-loop in the 3'-UTR of inflammatory mRNAs (e.g., Cxcl1) to assemble compartmentally distinct nuclear, P-body, and polysomal RNP complexes that prevent decay, block decapping, and promote translation, in part through ubiquitination of HuR and interaction with DDX3X [PMID:23772036, PMID:25710910, PMID:29563620]. Act1 signaling is constrained by TBK1/IKKi-mediated phosphorylation that disrupts Act1-TRAF6 binding and by SCFβ-TrCP-mediated Lys48 ubiquitination and degradation [PMID:22045853, PMID:22851696], and its folding and function depend on the chaperone Hsp90 [PMID:23202271]. Independently of IL-17 signaling, Act1 acts as a negative regulator: it attenuates CD40/BAFF-driven B cell survival via a TRAF3-dependent interaction [PMID:12089335, PMID:15485634, PMID:18061473, PMID:21948371] and directly inhibits STAT3 in T and B cells [PMID:30013031]. Human SEFIR-domain (T536I) and TRAF-domain (D10N) variants cause loss or impairment of IL-17 responsiveness and underlie chronic mucocutaneous candidiasis-type immunodeficiency and psoriasis susceptibility [PMID:24120361, PMID:23202271, PMID:20953186], while the oncogenic FYN-TRAF3IP2 fusion drives NF-κB-dependent peripheral T-cell lymphoma downstream of TCR activation [PMID:33928261].","teleology":[{"year":2000,"claim":"Established Act1/CIKS as a NEMO-binding activator of the IKK–NF-κB and JNK cascades, defining it as a signaling adaptor rather than an enzyme of unknown role.","evidence":"Reciprocal co-IP with NEMO, ectopic expression, NF-κB reporter and JNK assays with dominant-negative IKK in mammalian cells","pmids":["10962033","10962024"],"confidence":"High","gaps":["The upstream receptor was unidentified; the IL-1-unresponsive cell line implicated an unknown component","No endogenous-level mechanism or substrate defined"]},{"year":2002,"claim":"Placed TRAF6 immediately downstream of Act1 and showed Act1 engages CD40 receptor signaling, beginning to map the adaptor into specific receptor pathways.","evidence":"Co-IP with domain mapping, dominant-negative TRAF6 epistasis, and endogenous CD40 recruitment with rescue in epithelial cells","pmids":["12459498","12089335"],"confidence":"Medium","gaps":["TRAF6 selectivity established but biochemical mechanism of activation unknown","CD40 vs IL-1 pathway distinction not yet resolved"]},{"year":2004,"claim":"Revealed a context-dependent dual function: Act1 is a negative regulator of CD40/BAFF-mediated B cell survival, contrasting its activating role elsewhere.","evidence":"Genetic knockout with CD40-Act1 and BAFF-Act1 double-knockout epistasis and multi-pathway signaling immunoblots in B cells","pmids":["15485634"],"confidence":"High","gaps":["Molecular basis for the inhibitory (vs activating) outcome not defined","Domain requirements distinguishing the two roles unknown"]},{"year":2007,"claim":"Identified Act1 as the essential, non-redundant adaptor for IL-17 (and later IL-25) receptor signaling in vivo via SEFIR-domain recruitment, defining its principal physiological pathway.","evidence":"Genetic KO mice, primary astroglial/epithelial cells, co-IP defining the IL-17R–Act1–TRAF6–TAK1 complex, EAE and colitis disease models","pmids":["17277779","17035243","19155512","19155511"],"confidence":"High","gaps":["Structural basis of SEFIR-SEFIR specificity not yet resolved","Whether Act1 acts catalytically or only as scaffold unresolved at this stage"]},{"year":2009,"claim":"Demonstrated Act1 is itself a U-box E3 ligase that K63-ubiquitinates TRAF6 at K124, converting it from a passive scaffold to an active enzyme essential for IL-17-driven NF-κB.","evidence":"In vitro ubiquitination reconstitution with Ubc13-Uev1A, U-box and TRAF6-K124 mutagenesis, rescue of Act1-/- MEFs","pmids":["19825828"],"confidence":"High","gaps":["Whether all Act1 functions require ligase activity not established","Regulation of the ligase activity in vivo undefined"]},{"year":2011,"claim":"Defined the structural and regulatory logic of the IL-17R interaction and its negative control, including CC'-loop SEFIR binding and β-TrCP-mediated degradation.","evidence":"SPR binding of CC' loop peptide, mutagenesis of both partners, decoy-peptide inhibition in vivo, and co-IP/siRNA mapping of SCFβ-TrCP degradation","pmids":["22045852","22045853"],"confidence":"High","gaps":["Kinase generating the phosphodegron not identified in this work","Stoichiometry of degradative vs signaling pools unknown"]},{"year":2012,"claim":"Resolved how Act1 stability and signaling are gated by Hsp90 chaperoning and by TBK1/IKKi phosphorylation that uncouples Act1 from TRAF6, and linked the D10N variant to psoriasis.","evidence":"Co-IP of Act1-Hsp90 and Act1-TBK1, in vitro kinase assay with site mutagenesis, conditional KO mice and in vivo cytokine neutralization","pmids":["23202271","22851696"],"confidence":"High","gaps":["How phosphorylation and degradation feedback are temporally coordinated unclear","Hsp90 client maturation steps not defined"]},{"year":2013,"claim":"Established Act1 as a post-transcriptional regulator that stabilizes inflammatory mRNAs via HuR, and confirmed human disease causation through the SEFIR-domain T536I mutation.","evidence":"HuR KO, Act1-HuR co-IP, polysome fractionation, mRNA decay assays; patient-derived fibroblasts/T cells with co-IP of mutant ACT1","pmids":["23772036","24120361"],"confidence":"High","gaps":["Direct RNA-binding element on target mRNAs not yet mapped","Genotype–phenotype distinction between SEFIR and TRAF-domain mutations only partially defined"]},{"year":2015,"claim":"Extended the RNA-regulatory mechanism by showing Act1 partners with DDX3X (and TRAF2/TRAF5/IKKε) to selectively stabilize specific transcripts such as Zc3h12a.","evidence":"Co-IP of CIKS-DDX3X with helicase-domain requirement, DDX3X knockdown, RIP and mRNA stability assays","pmids":["25710910"],"confidence":"Medium","gaps":["Single lab; transcript selectivity mechanism incompletely defined","Relationship between DDX3X and HuR pathways not integrated"]},{"year":2018,"claim":"Unified the RNA function into a structural model where Act1 binds a 3'-UTR SEFIR-binding element to assemble compartment-specific RNPs, and revealed a separable IL-17-independent role inhibiting STAT3.","evidence":"RIP, RNA structure mapping, polysome profiling, P-body imaging, aptamer therapy in vivo; mass spectrometry of Act1-STAT3 with comparative KO mice","pmids":["29563620","30013031"],"confidence":"High","gaps":["How Act1 distributes between cytoplasmic signaling, RNP, and nuclear STAT3-inhibitory pools is unresolved","Mechanism of direct STAT3 inhibition not biochemically defined"]},{"year":2021,"claim":"Showed that genomic fusion of TRAF3IP2 to FYN constitutively drives NF-κB signaling and T-cell transformation, establishing an oncogenic gain-of-function for the adaptor.","evidence":"RNA-seq fusion identification, mouse hematopoietic progenitor transformation, Tet2-loss cooperation, IKK inhibitor treatment in vitro and in vivo","pmids":["33928261"],"confidence":"High","gaps":["Molecular mechanism by which the FYN moiety activates Act1-NF-κB output not fully defined","Whether endogenous Act1 enzymatic functions are required for transformation unknown"]},{"year":null,"claim":"How a single adaptor is partitioned among its activating (IL-17R/TRAF6/NF-κB), post-transcriptional (RNP/HuR/DDX3X), and inhibitory (CD40/BAFF, STAT3) functions, and how its phosphorylation, ubiquitination, and chaperoning are integrated to dictate these outcomes, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model of Act1 pool partitioning across compartments","Regulatory hierarchy linking TBK1 phosphorylation, β-TrCP degradation, and Hsp90 chaperoning not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[9]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[9]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[6,7,14]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,1,2,7]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[20,27]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,1,6,7]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[27]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[6,7,14]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,7,10,28]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,7,9]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[20,26,27]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[16,19,29]}],"complexes":["IL-17 receptor signaling complex (IL-17RA–Act1–TRAF6–TAK1)","SCFβ-TrCP E3 ligase complex (substrate)"],"partners":["IL17RA","TRAF6","NEMO/IKBKG","TRAF3","HUR/ELAVL1","DDX3X","STAT3","HSP90"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O43734","full_name":"E3 ubiquitin ligase TRAF3IP2","aliases":["Adapter protein CIKS","Connection to IKK and SAPK/JNK","E3 ubiquitin-protein ligase CIKS","Nuclear factor NF-kappa-B activator 1","ACT1","TRAF3-interacting protein 2"],"length_aa":574,"mass_kda":64.7,"function":"E3 ubiquitin ligase that catalyzes 'Lys-63'-linked polyubiquitination of target protein, enhancing protein-protein interaction and cell signaling (PubMed:19825828). Transfers ubiquitin from E2 ubiquitin-conjugating enzyme UBE2V1-UBE2N to substrate protein (PubMed:19825828). Essential adapter molecule in IL17A-mediated signaling (PubMed:19825828, PubMed:24120361). Upon IL17A stimulation, interacts with IL17RA and IL17RC receptor chains through SEFIR domains and catalyzes 'Lys-63'-linked polyubiquitination of TRAF6, leading to TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways (PubMed:19825828)","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/O43734/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TRAF3IP2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TRAF3IP2","total_profiled":1310},"omim":[{"mim_id":"615527","title":"CANDIDIASIS, FAMILIAL, 8; CANDF8","url":"https://www.omim.org/entry/615527"},{"mim_id":"614995","title":"INTERLEUKIN 17 RECEPTOR E; IL17RE","url":"https://www.omim.org/entry/614995"},{"mim_id":"614070","title":"PSORIASIS 13, SUSCEPTIBILITY TO; PSORS13","url":"https://www.omim.org/entry/614070"},{"mim_id":"611831","title":"MITOCHONDRIAL RIBOSOMAL PROTEIN L18; MRPL18","url":"https://www.omim.org/entry/611831"},{"mim_id":"608004","title":"NUCLEAR FACTOR KAPPA-B INHIBITOR, ZETA; NFKBIZ","url":"https://www.omim.org/entry/608004"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TRAF3IP2"},"hgnc":{"alias_symbol":["DKFZP586G0522","ACT1","CIKS"],"prev_symbol":["C6orf4","C6orf5","C6orf6","C6orf2"]},"alphafold":{"accession":"O43734","domains":[{"cath_id":"3.40.50.11530","chopping":"408-554","consensus_level":"high","plddt":86.2789,"start":408,"end":554}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O43734","model_url":"https://alphafold.ebi.ac.uk/files/AF-O43734-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O43734-F1-predicted_aligned_error_v6.png","plddt_mean":53.22},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TRAF3IP2","jax_strain_url":"https://www.jax.org/strain/search?query=TRAF3IP2"},"sequence":{"accession":"O43734","fasta_url":"https://rest.uniprot.org/uniprotkb/O43734.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O43734/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O43734"}},"corpus_meta":[{"pmid":"17277779","id":"PMC_17277779","title":"The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease.","date":"2007","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17277779","citation_count":504,"is_preprint":false},{"pmid":"9055993","id":"PMC_9055993","title":"Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein.","date":"1997","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/9055993","citation_count":366,"is_preprint":false},{"pmid":"1427032","id":"PMC_1427032","title":"Systematic mutational analysis of the yeast ACT1 gene.","date":"1992","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1427032","citation_count":306,"is_preprint":false},{"pmid":"20953186","id":"PMC_20953186","title":"Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20953186","citation_count":300,"is_preprint":false},{"pmid":"17035243","id":"PMC_17035243","title":"Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17035243","citation_count":299,"is_preprint":false},{"pmid":"20303295","id":"PMC_20303295","title":"Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis.","date":"2010","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/20303295","citation_count":240,"is_preprint":false},{"pmid":"24120361","id":"PMC_24120361","title":"An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis.","date":"2013","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/24120361","citation_count":231,"is_preprint":false},{"pmid":"19825828","id":"PMC_19825828","title":"Act1, a U-box E3 ubiquitin ligase for IL-17 signaling.","date":"2009","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/19825828","citation_count":193,"is_preprint":false},{"pmid":"23995070","id":"PMC_23995070","title":"Act1 mediates IL-17-induced EAE pathogenesis selectively in NG2+ glial cells.","date":"2013","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23995070","citation_count":180,"is_preprint":false},{"pmid":"17982039","id":"PMC_17982039","title":"Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-kappaB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17982039","citation_count":179,"is_preprint":false},{"pmid":"9227855","id":"PMC_9227855","title":"Actin in the parasite Toxoplasma gondii is encoded by a single copy gene, ACT1 and exists primarily in a globular form.","date":"1997","source":"Cell motility and the cytoskeleton","url":"https://pubmed.ncbi.nlm.nih.gov/9227855","citation_count":154,"is_preprint":false},{"pmid":"10962024","id":"PMC_10962024","title":"Act1, an NF-kappa B-activating protein.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10962024","citation_count":145,"is_preprint":false},{"pmid":"1753941","id":"PMC_1753941","title":"Construction of expression vectors based on the rice actin 1 (Act1) 5' region for use in monocot transformation.","date":"1991","source":"Molecular & general genetics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/1753941","citation_count":143,"is_preprint":false},{"pmid":"10962033","id":"PMC_10962033","title":"CIKS, a connection to Ikappa B kinase and stress-activated protein kinase.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10962033","citation_count":132,"is_preprint":false},{"pmid":"21335551","id":"PMC_21335551","title":"IL-17-induced NF-kappaB activation via CIKS/Act1: physiologic significance and signaling mechanisms.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21335551","citation_count":127,"is_preprint":false},{"pmid":"10463153","id":"PMC_10463153","title":"Phylogenetic analysis and rapid identification of Candida dubliniensis based on analysis of ACT1 intron and exon sequences.","date":"1999","source":"Microbiology (Reading, England)","url":"https://pubmed.ncbi.nlm.nih.gov/10463153","citation_count":122,"is_preprint":false},{"pmid":"1821763","id":"PMC_1821763","title":"Analysis of rice Act1 5' region activity in transgenic rice plants.","date":"1991","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/1821763","citation_count":118,"is_preprint":false},{"pmid":"15485634","id":"PMC_15485634","title":"Act1, a negative regulator in CD40- and BAFF-mediated B cell survival.","date":"2004","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/15485634","citation_count":115,"is_preprint":false},{"pmid":"19155512","id":"PMC_19155512","title":"The critical role of epithelial-derived Act1 in IL-17- and IL-25-mediated pulmonary inflammation.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19155512","citation_count":114,"is_preprint":false},{"pmid":"19155511","id":"PMC_19155511","title":"The adaptor protein CIKS/Act1 is essential for IL-25-mediated allergic airway inflammation.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19155511","citation_count":113,"is_preprint":false},{"pmid":"24561578","id":"PMC_24561578","title":"OxLDL induces endothelial dysfunction and death via TRAF3IP2: inhibition by HDL3 and AMPK activators.","date":"2014","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24561578","citation_count":105,"is_preprint":false},{"pmid":"29563620","id":"PMC_29563620","title":"IL-17-receptor-associated adaptor Act1 directly stabilizes mRNAs to mediate IL-17 inflammatory signaling.","date":"2018","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29563620","citation_count":102,"is_preprint":false},{"pmid":"33160017","id":"PMC_33160017","title":"The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion.","date":"2020","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/33160017","citation_count":101,"is_preprint":false},{"pmid":"31862399","id":"PMC_31862399","title":"Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition.","date":"2019","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/31862399","citation_count":96,"is_preprint":false},{"pmid":"22511335","id":"PMC_22511335","title":"IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner.","date":"2012","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22511335","citation_count":90,"is_preprint":false},{"pmid":"23202271","id":"PMC_23202271","title":"The psoriasis-associated D10N variant of the adaptor Act1 with impaired regulation by the molecular chaperone hsp90.","date":"2012","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23202271","citation_count":90,"is_preprint":false},{"pmid":"22744010","id":"PMC_22744010","title":"Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients.","date":"2012","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/22744010","citation_count":89,"is_preprint":false},{"pmid":"30528823","id":"PMC_30528823","title":"Neutrophil Extracellular Traps Induce Human Th17 Cells: Effect of Psoriasis-Associated TRAF3IP2 Genotype.","date":"2018","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/30528823","citation_count":87,"is_preprint":false},{"pmid":"23772036","id":"PMC_23772036","title":"HuR is required for IL-17-induced Act1-mediated CXCL1 and CXCL5 mRNA stabilization.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23772036","citation_count":87,"is_preprint":false},{"pmid":"22851696","id":"PMC_22851696","title":"TRAF6-dependent Act1 phosphorylation by the IκB kinase-related kinases suppresses interleukin-17-induced NF-κB activation.","date":"2012","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22851696","citation_count":79,"is_preprint":false},{"pmid":"36411467","id":"PMC_36411467","title":"Salidroside attenuates HALI via IL-17A-mediated ferroptosis of alveolar epithelial cells by regulating Act1-TRAF6-p38 MAPK pathway.","date":"2022","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/36411467","citation_count":77,"is_preprint":false},{"pmid":"27980343","id":"PMC_27980343","title":"IL-17A exacerbates diabetic retinopathy by impairing Müller cell function via Act1 signaling.","date":"2016","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27980343","citation_count":76,"is_preprint":false},{"pmid":"18061473","id":"PMC_18061473","title":"Act1 modulates autoimmunity through its dual functions in CD40L/BAFF and IL-17 signaling.","date":"2007","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/18061473","citation_count":61,"is_preprint":false},{"pmid":"22608496","id":"PMC_22608496","title":"Epithelial cell-specific Act1 adaptor mediates interleukin-25-dependent helminth expulsion through expansion of Lin(-)c-Kit(+) innate cell population.","date":"2012","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/22608496","citation_count":61,"is_preprint":false},{"pmid":"12574281","id":"PMC_12574281","title":"Occurrence of extended-spectrum and AmpC beta-lactamases in bloodstream isolates of Klebsiella pneumoniae: isolates harbor plasmid-mediated FOX-5 and ACT-1 AmpC beta-lactamases.","date":"2003","source":"Journal of clinical microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/12574281","citation_count":61,"is_preprint":false},{"pmid":"18624351","id":"PMC_18624351","title":"Deficiency of Act1, a critical modulator of B cell function, leads to development of Sjögren's syndrome.","date":"2008","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18624351","citation_count":58,"is_preprint":false},{"pmid":"25202827","id":"PMC_25202827","title":"Syk mediates IL-17-induced CCL20 expression by targeting Act1-dependent K63-linked ubiquitination of TRAF6.","date":"2014","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/25202827","citation_count":57,"is_preprint":false},{"pmid":"22699909","id":"PMC_22699909","title":"IL-17-induced Act1-mediated signaling is critical for cuprizone-induced demyelination.","date":"2012","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/22699909","citation_count":57,"is_preprint":false},{"pmid":"33741027","id":"PMC_33741027","title":"Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N6-methyladenosine of PARP1 mRNA and downregulating PTEN.","date":"2021","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33741027","citation_count":56,"is_preprint":false},{"pmid":"28476142","id":"PMC_28476142","title":"Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice.","date":"2017","source":"Cardiovascular diabetology","url":"https://pubmed.ncbi.nlm.nih.gov/28476142","citation_count":56,"is_preprint":false},{"pmid":"26148936","id":"PMC_26148936","title":"Aldosterone-induced cardiomyocyte growth, and fibroblast migration and proliferation are mediated by TRAF3IP2.","date":"2015","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/26148936","citation_count":54,"is_preprint":false},{"pmid":"25881004","id":"PMC_25881004","title":"Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25881004","citation_count":53,"is_preprint":false},{"pmid":"23453926","id":"PMC_23453926","title":"Advanced oxidation protein products induce cardiomyocyte death via Nox2/Rac1/superoxide-dependent TRAF3IP2/JNK signaling.","date":"2013","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23453926","citation_count":52,"is_preprint":false},{"pmid":"24892823","id":"PMC_24892823","title":"Interleukin-17A promotes MUC5AC expression and goblet cell hyperplasia in nasal polyps via the Act1-mediated pathway.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24892823","citation_count":52,"is_preprint":false},{"pmid":"23836313","id":"PMC_23836313","title":"TRAF3IP2 gene and systemic lupus erythematosus: association with disease susceptibility and pericarditis development.","date":"2013","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/23836313","citation_count":50,"is_preprint":false},{"pmid":"35304250","id":"PMC_35304250","title":"IL-17A Promotes Psoriasis-Associated Keratinocyte Proliferation through ACT1-Dependent Activation of YAP-AREG Axis.","date":"2022","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/35304250","citation_count":49,"is_preprint":false},{"pmid":"22575763","id":"PMC_22575763","title":"CIKS (Act1 or TRAF3IP2) mediates Angiotensin-II-induced Interleukin-18 expression, and Nox2-dependent cardiomyocyte hypertrophy.","date":"2012","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/22575763","citation_count":49,"is_preprint":false},{"pmid":"12089335","id":"PMC_12089335","title":"Role of NF kappa B activator Act1 in CD40-mediated signaling in epithelial cells.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12089335","citation_count":49,"is_preprint":false},{"pmid":"22045853","id":"PMC_22045853","title":"Persistent stimulation with interleukin-17 desensitizes cells through SCFβ-TrCP-mediated degradation of Act1.","date":"2011","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/22045853","citation_count":47,"is_preprint":false},{"pmid":"22045852","id":"PMC_22045852","title":"A CC' loop decoy peptide blocks the interaction between Act1 and IL-17RA to attenuate IL-17- and IL-25-induced inflammation.","date":"2011","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/22045852","citation_count":46,"is_preprint":false},{"pmid":"8243992","id":"PMC_8243992","title":"Screens for extragenic mutations that fail to complement act1 alleles identify genes that are important for actin function in Saccharomyces cerevisiae.","date":"1993","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8243992","citation_count":46,"is_preprint":false},{"pmid":"22445837","id":"PMC_22445837","title":"TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in inflammatory bowel disease.","date":"2012","source":"Journal of Crohn's & colitis","url":"https://pubmed.ncbi.nlm.nih.gov/22445837","citation_count":44,"is_preprint":false},{"pmid":"12023082","id":"PMC_12023082","title":"Chromosomal ampC genes in Enterobacter species other than Enterobacter cloacae, and ancestral association of the ACT-1 plasmid-encoded cephalosporinase to Enterobacter asburiae.","date":"2002","source":"FEMS microbiology letters","url":"https://pubmed.ncbi.nlm.nih.gov/12023082","citation_count":40,"is_preprint":false},{"pmid":"23085260","id":"PMC_23085260","title":"CIKS (Act1 or TRAF3IP2) mediates high glucose-induced endothelial dysfunction.","date":"2012","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/23085260","citation_count":39,"is_preprint":false},{"pmid":"16524910","id":"PMC_16524910","title":"The actin gene ACT1 is required for phagocytosis, motility, and cell separation of Tetrahymena thermophila.","date":"2006","source":"Eukaryotic cell","url":"https://pubmed.ncbi.nlm.nih.gov/16524910","citation_count":39,"is_preprint":false},{"pmid":"21856933","id":"PMC_21856933","title":"T cell-derived Act1 is necessary for IL-25-mediated Th2 responses and allergic airway inflammation.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21856933","citation_count":38,"is_preprint":false},{"pmid":"12459498","id":"PMC_12459498","title":"NF-kappaB activator Act1 associates with IL-1/Toll pathway adaptor molecule TRAF6.","date":"2002","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/12459498","citation_count":38,"is_preprint":false},{"pmid":"30013031","id":"PMC_30013031","title":"Act1 is a negative regulator in T and B cells via direct inhibition of STAT3.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30013031","citation_count":37,"is_preprint":false},{"pmid":"19407614","id":"PMC_19407614","title":"The connexin43 carboxyl-terminal peptide ACT1 modulates the biological response to silicone implants.","date":"2009","source":"Plastic and reconstructive surgery","url":"https://pubmed.ncbi.nlm.nih.gov/19407614","citation_count":37,"is_preprint":false},{"pmid":"29981796","id":"PMC_29981796","title":"TRAF3IP2 mediates TWEAK/TWEAKR-induced pro-fibrotic responses in cultured cardiac fibroblasts and the heart.","date":"2018","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/29981796","citation_count":36,"is_preprint":false},{"pmid":"25710910","id":"PMC_25710910","title":"CIKS/DDX3X interaction controls the stability of the Zc3h12a mRNA induced by IL-17.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25710910","citation_count":36,"is_preprint":false},{"pmid":"30989715","id":"PMC_30989715","title":"microRNA-340-5p inhibits hypoxia/reoxygenation-induced apoptosis and oxidative stress in cardiomyocytes by regulating the Act1/NF-κB pathway.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30989715","citation_count":36,"is_preprint":false},{"pmid":"19159390","id":"PMC_19159390","title":"A protein secreted by the respiratory pathogen Chlamydia pneumoniae impairs IL-17 signalling via interaction with human Act1.","date":"2009","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/19159390","citation_count":36,"is_preprint":false},{"pmid":"23116200","id":"PMC_23116200","title":"New insight into the functions of the interleukin-17 receptor adaptor protein Act1 in psoriatic arthritis.","date":"2012","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/23116200","citation_count":35,"is_preprint":false},{"pmid":"31239234","id":"PMC_31239234","title":"Diabetes induces IL-17A-Act1-FADD-dependent retinal endothelial cell death and capillary degeneration.","date":"2019","source":"Journal of diabetes and its complications","url":"https://pubmed.ncbi.nlm.nih.gov/31239234","citation_count":35,"is_preprint":false},{"pmid":"11864960","id":"PMC_11864960","title":"The ACT-1 plasmid-encoded AmpC beta-lactamase is inducible: detection in a complex beta-lactamase background.","date":"2002","source":"The Journal of antimicrobial chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/11864960","citation_count":35,"is_preprint":false},{"pmid":"31074012","id":"PMC_31074012","title":"RECK suppresses interleukin-17/TRAF3IP2-mediated MMP-13 activation and human aortic smooth muscle cell migration and proliferation.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31074012","citation_count":33,"is_preprint":false},{"pmid":"24816115","id":"PMC_24816115","title":"Structure of the unique SEFIR domain from human interleukin 17 receptor A reveals a composite ligand-binding site containing a conserved α-helix for Act1 binding and IL-17 signaling.","date":"2014","source":"Acta crystallographica. Section D, Biological crystallography","url":"https://pubmed.ncbi.nlm.nih.gov/24816115","citation_count":33,"is_preprint":false},{"pmid":"28971844","id":"PMC_28971844","title":"TRAF3IP2 mediates high glucose-induced endothelin-1 production as well as endothelin-1-induced inflammation in endothelial cells.","date":"2017","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28971844","citation_count":32,"is_preprint":false},{"pmid":"20662069","id":"PMC_20662069","title":"The adaptor protein CIKS/ACT1 is necessary for collagen-induced arthritis, and it contributes to the production of collagen-specific antibody.","date":"2010","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/20662069","citation_count":29,"is_preprint":false},{"pmid":"28053087","id":"PMC_28053087","title":"Targeting TRAF3IP2 by Genetic and Interventional Approaches Inhibits Ischemia/Reperfusion-induced Myocardial Injury and Adverse Remodeling.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28053087","citation_count":29,"is_preprint":false},{"pmid":"27040306","id":"PMC_27040306","title":"TRAF3IP2 mediates aldosterone/salt-induced cardiac hypertrophy and fibrosis.","date":"2016","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27040306","citation_count":29,"is_preprint":false},{"pmid":"20660351","id":"PMC_20660351","title":"An atopic dermatitis-like skin disease with hyper-IgE-emia develops in mice carrying a spontaneous recessive point mutation in the Traf3ip2 (Act1/CIKS) gene.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20660351","citation_count":29,"is_preprint":false},{"pmid":"31630418","id":"PMC_31630418","title":"IL-17 stimulates the expression of CCL2 in cardiac myocytes via Act1/TRAF6/p38MAPK-dependent AP-1 activation.","date":"2019","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31630418","citation_count":29,"is_preprint":false},{"pmid":"11014803","id":"PMC_11014803","title":"Suppressors of mdm20 in yeast identify new alleles of ACT1 and TPM1 predicted to enhance actin-tropomyosin interactions.","date":"2000","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11014803","citation_count":29,"is_preprint":false},{"pmid":"30882006","id":"PMC_30882006","title":"STAT4, TRAF3IP2, IL10, and HCP5 Polymorphisms in Sjögren's Syndrome: Association with Disease Susceptibility and Clinical Aspects.","date":"2019","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/30882006","citation_count":28,"is_preprint":false},{"pmid":"23872479","id":"PMC_23872479","title":"TRAF3IP2 mediates interleukin-18-induced cardiac fibroblast migration and differentiation.","date":"2013","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/23872479","citation_count":28,"is_preprint":false},{"pmid":"30892082","id":"PMC_30892082","title":"MLN4924 protects against interleukin-17A-induced pulmonary inflammation by disrupting ACT1-mediated signaling.","date":"2019","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30892082","citation_count":28,"is_preprint":false},{"pmid":"33928261","id":"PMC_33928261","title":"FYN-TRAF3IP2 induces NF-κB signaling-driven peripheral T cell lymphoma.","date":"2021","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33928261","citation_count":27,"is_preprint":false},{"pmid":"33941656","id":"PMC_33941656","title":"Identification of a Long Noncoding RNA TRAF3IP2-AS1 as Key Regulator of IL-17 Signaling through the SRSF10-IRF1-Act1 Axis in Autoimmune Diseases.","date":"2021","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/33941656","citation_count":27,"is_preprint":false},{"pmid":"28274739","id":"PMC_28274739","title":"Dual Role of Act1 in Keratinocyte Differentiation and Host Defense: TRAF3IP2 Silencing Alters Keratinocyte Differentiation and Inhibits IL-17 Responses.","date":"2017","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/28274739","citation_count":27,"is_preprint":false},{"pmid":"34140493","id":"PMC_34140493","title":"Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34140493","citation_count":27,"is_preprint":false},{"pmid":"30021197","id":"PMC_30021197","title":"MiR-298 Exacerbates Ischemia/Reperfusion Injury Following Ischemic Stroke by Targeting Act1.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30021197","citation_count":27,"is_preprint":false},{"pmid":"17684298","id":"PMC_17684298","title":"A role for the cytoplasmic adaptor protein Act1 in mediating IL-17 signaling.","date":"2007","source":"Science's STKE : signal transduction knowledge environment","url":"https://pubmed.ncbi.nlm.nih.gov/17684298","citation_count":26,"is_preprint":false},{"pmid":"21948371","id":"PMC_21948371","title":"Function of Act1 in IL-17 family signaling and autoimmunity.","date":"2012","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/21948371","citation_count":26,"is_preprint":false},{"pmid":"24416204","id":"PMC_24416204","title":"TRAF5 and TRAF3IP2 gene polymorphisms are associated with Behçet's disease and Vogt-Koyanagi-Harada syndrome: a case-control study.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24416204","citation_count":26,"is_preprint":false},{"pmid":"16480328","id":"PMC_16480328","title":"Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients.","date":"2006","source":"Cancer biotherapy & radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/16480328","citation_count":26,"is_preprint":false},{"pmid":"33748112","id":"PMC_33748112","title":"Downregulation of Macrophage-Specific Act-1 Intensifies Periodontitis and Alveolar Bone Loss Possibly via TNF/NF-κB Signaling.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33748112","citation_count":25,"is_preprint":false},{"pmid":"22581863","id":"PMC_22581863","title":"CIKS/Act1-mediated signaling by IL-17 cytokines in context: implications for how a CIKS gene variant may predispose to psoriasis.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22581863","citation_count":24,"is_preprint":false},{"pmid":"27097970","id":"PMC_27097970","title":"Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.","date":"2016","source":"Radiation oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/27097970","citation_count":24,"is_preprint":false},{"pmid":"12943667","id":"PMC_12943667","title":"Role of the adaptor protein CIKS in the activation of the IKK complex.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12943667","citation_count":23,"is_preprint":false},{"pmid":"1986221","id":"PMC_1986221","title":"A chicken beta-actin gene can complement a disruption of the Saccharomyces cerevisiae ACT1 gene.","date":"1991","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1986221","citation_count":23,"is_preprint":false},{"pmid":"31292894","id":"PMC_31292894","title":"Chronic Mucocutaneous Candidiasis in an Adolescent Boy Due to a Novel Mutation in TRAF3IP2.","date":"2019","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31292894","citation_count":22,"is_preprint":false},{"pmid":"21643828","id":"PMC_21643828","title":"Evolution of vertebrate immunity: sequence and functional analysis of the SEFIR domain family member Act1.","date":"2011","source":"Journal of molecular evolution","url":"https://pubmed.ncbi.nlm.nih.gov/21643828","citation_count":22,"is_preprint":false},{"pmid":"37098777","id":"PMC_37098777","title":"IL-23/IL-17 immune axis mediates the imiquimod-induced psoriatic inflammation by activating ACT1/TRAF6/TAK1/NF-κB pathway in macrophages and keratinocytes.","date":"2023","source":"The Kaohsiung journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37098777","citation_count":20,"is_preprint":false},{"pmid":"25024377","id":"PMC_25024377","title":"The differential regulation of human ACT1 isoforms by Hsp90 in IL-17 signaling.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25024377","citation_count":20,"is_preprint":false},{"pmid":"29080697","id":"PMC_29080697","title":"Upregulation of miR-215 exerts neuroprotection effects against ischemic injury via negative regulation of Act1/IL-17RA signaling.","date":"2017","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/29080697","citation_count":20,"is_preprint":false},{"pmid":"27466370","id":"PMC_27466370","title":"Cardiac-restricted Overexpression of TRAF3 Interacting Protein 2 (TRAF3IP2) Results in Spontaneous Development of Myocardial Hypertrophy, Fibrosis, and Dysfunction.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27466370","citation_count":19,"is_preprint":false},{"pmid":"20543113","id":"PMC_20543113","title":"The adaptor molecule Act1 regulates BAFF responsiveness and self-reactive B cell selection during transitional B cell maturation.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20543113","citation_count":19,"is_preprint":false},{"pmid":"32829657","id":"PMC_32829657","title":"TRAF3IP2 (TRAF3 Interacting Protein 2) Mediates Obesity-Associated Vascular Insulin Resistance and Dysfunction in Male Mice.","date":"2020","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/32829657","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52895,"output_tokens":8766,"usd":0.145088,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18786,"output_tokens":4672,"usd":0.105365,"stage2_stop_reason":"end_turn"},"total_usd":0.250453,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"Act1/CIKS was identified as a novel protein that directly interacts with NEMO/IKKγ in cells. When ectopically expressed, CIKS stimulates IKK and SAPK/JNK kinases and transactivates an NF-κB-dependent reporter, with NF-κB activation prevented by kinase-deficient IKK mutants.\",\n      \"method\": \"Co-immunoprecipitation, ectopic expression, NF-κB reporter assay, dominant-negative kinase mutants\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent papers (PMID 10962024 and 10962033) published simultaneously identified the same protein by different labs using reciprocal co-IP and functional reporter assays\",\n      \"pmids\": [\"10962033\", \"10962024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Act1 associates with and activates IκB kinase (IKK), leading to liberation of NF-κB from its IκB complex, and also activates JNK. Act1 failed to activate NF-κB in an IL-1-unresponsive mutant cell line despite all known signaling components being present, suggesting interaction with an unknown component of IL-1 signaling.\",\n      \"method\": \"Co-immunoprecipitation, NF-κB reporter assay, JNK kinase assay, IL-1-unresponsive mutant cell line\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP and functional assays in a defined genetic background, replicated across two simultaneous papers\",\n      \"pmids\": [\"10962024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Act1 interacts with TRAF6 specifically (not other TRAF family members) via its amino-terminal half, and Act1-mediated NF-κB activation is inhibited by a dominant-negative TRAF6 mutant in a dose-dependent manner, placing TRAF6 downstream of Act1 in IL-1/Toll-mediated signaling.\",\n      \"method\": \"Co-immunoprecipitation, dominant-negative TRAF6, NF-κB reporter assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP with domain mapping and dominant-negative epistasis, single lab\",\n      \"pmids\": [\"12459498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Endogenous Act1 is recruited to the CD40 receptor in epithelial cells upon CD40L stimulation, and Act1 interacts with TRAF3 (a CD40-associated component). Transfection of Act1 into Act1-negative cervical epithelial cells renders them sensitive to CD40L-induced NF-κB activation and protects them from CD40L-induced apoptosis.\",\n      \"method\": \"Co-immunoprecipitation of endogenous proteins, ectopic expression rescue, NF-κB reporter assay, apoptosis assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — endogenous Co-IP and functional rescue experiments, single lab\",\n      \"pmids\": [\"12089335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CIKS/Act1 forms homo-oligomers, interacts with NEMO/IKKγ, and is recruited to the IKK complex upon cell stimulation. A deletion mutant that retains oligomerization and NEMO binding but lacks a second domain fails to activate NF-κB, indicating that recruitment to IKK is necessary but not sufficient for NF-κB activation.\",\n      \"method\": \"Co-immunoprecipitation, deletion mutagenesis, NF-κB reporter assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain deletion mutagenesis with functional readout, single lab\",\n      \"pmids\": [\"12943667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Act1 functions as a negative regulator of CD40- and BAFF-mediated B cell survival. Act1 deficiency leads to stronger IκB phosphorylation, processing of NF-κB2 (p100/p52), and activation of JNK, ERK, and p38 pathways in B cells. The phenotype is largely blocked in CD40-Act1 and BAFF-Act1 double-knockout mice, genetically placing Act1 downstream of CD40 and BAFFR.\",\n      \"method\": \"Genetic knockout, double-knockout epistasis, signaling pathway analysis by immunoblot\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with double-KO epistasis and defined signaling phenotype, multiple orthogonal readouts\",\n      \"pmids\": [\"15485634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Act1 directly associates with IL-17 receptor (IL-17RA) likely via homotypic SEFIR domain interaction and acts as a membrane-proximal adaptor. Deficiency of Act1 in fibroblasts abrogates IL-17-induced cytokine and chemokine expression, C/EBPβ, C/EBPδ, and IκBζ induction, and NF-κB pathway activation.\",\n      \"method\": \"Co-immunoprecipitation, Act1-deficient fibroblasts, immunoblot/qPCR for downstream targets\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct physical interaction and loss-of-function in primary cells with multiple orthogonal readouts, replicated in subsequent papers\",\n      \"pmids\": [\"17035243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Act1 is essential for IL-17 receptor (IL-17R) signaling in vivo. After IL-17 stimulation, Act1 is recruited to IL-17R via SEFIR domain interaction, followed by recruitment of TAK1 and TRAF6 to mediate NF-κB activation. Act1-deficient primary astroglial and gut epithelial cells showed abolished IL-17-induced inflammatory gene expression, and Act1-deficient mice showed reduced EAE and DSS-induced colitis.\",\n      \"method\": \"Genetic knockout mouse, primary cell studies, co-immunoprecipitation, SEFIR domain analysis, in vivo disease models\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with defined in vivo phenotypes, co-IP defining the receptor complex, replicated across multiple disease models and cell types\",\n      \"pmids\": [\"17277779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Two independent signaling pathways are required for IL-17A-induced gene expression in human airway epithelial cells: (1) a JAK1-associated PI3K signaling axis independent of NF-κB, and (2) an Act1/TRAF6/TAK1-mediated NF-κB activation pathway. siRNA knockdown of Act1, TRAF6, or TAK1 reduced IL-17A-inducible gene expression and NF-κB activation.\",\n      \"method\": \"siRNA knockdown, PI3K inhibitor, JAK inhibitor, NF-κB DNA-binding assay, promoter activity assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with functional readouts, multiple inhibitors, single lab\",\n      \"pmids\": [\"17982039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Act1 is a U-box E3 ubiquitin ligase. Using the Ubc13-Uev1A E2 complex, Act1 mediates Lys63-linked ubiquitination of TRAF6, and this activity is essential for IL-17-mediated NF-κB signaling. Deletion and point mutations of the Act1 U-box abolished TRAF6 ubiquitination and impaired IL-17-dependent signaling and gene expression in Act1-/- MEFs. Lys-124 of TRAF6 was identified as a critical ubiquitination site.\",\n      \"method\": \"In vitro ubiquitination assay, U-box point mutagenesis, rescue of Act1-/- MEFs, immunoblot for K63-linked ubiquitin chains, site-directed mutagenesis of TRAF6-K124\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro ubiquitination reconstitution with mutagenesis of both enzyme (U-box) and substrate (K124), validated in primary cells\",\n      \"pmids\": [\"19825828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Act1 is an essential signaling molecule for IL-25 (IL-17E) receptor signaling in addition to IL-17 receptor signaling. Act1 deficiency abolished IL-25-induced expression of IL-4, IL-5, IL-13, eotaxin-1, and pulmonary eosinophilia in mice.\",\n      \"method\": \"Act1-deficient mice, cytokine/chemokine expression assays, pulmonary inflammation model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with defined in vivo phenotype, replicated by two independent labs in same issue\",\n      \"pmids\": [\"19155512\", \"19155511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Act1 deficiency specifically in neuroectoderm-derived CNS-resident cells (neurons, astrocytes, oligodendrocytes) markedly reduced EAE severity. Act1-deficient astrocytes showed impaired IL-17-mediated inflammatory gene induction, identifying astrocytes as critical cellular targets of IL-17-Act1 signaling in CNS inflammation.\",\n      \"method\": \"Conditional cell-type-specific Act1 knockout mice, EAE model, gene expression analysis in primary astrocytes\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional cell-type-specific KO with defined in vivo phenotype and in vitro mechanistic confirmation\",\n      \"pmids\": [\"20303295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CIKS/Act1 is essential for all IL-17-induced immediate-early genes in primary mouse embryo fibroblasts. A novel N-terminal subdomain of CIKS is both necessary and sufficient for interaction with TRAF6 and for IL-17-mediated NF-κB activation.\",\n      \"method\": \"CIKS-deficient MEFs, domain deletion mutagenesis, Co-IP, NF-κB reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain mapping with functional readouts in primary cells, single lab\",\n      \"pmids\": [\"21335551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Persistent IL-17 stimulation leads to Lys48-linked polyubiquitination and degradation of Act1 in a phosphorylation-dependent manner via SCFβ-TrCP E3 ligase complexes (containing β-TrCP1 or β-TrCP2), desensitizing IL-17R signaling. Dominant-negative β-TrCP or knockdown of β-TrCP1/2 markedly reduced IL-17-induced Act1 ubiquitination and degradation.\",\n      \"method\": \"Co-immunoprecipitation of Act1 with β-TrCP, dominant-negative β-TrCP, siRNA knockdown, ubiquitin linkage analysis\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, dominant-negative, and siRNA approaches converge, single lab\",\n      \"pmids\": [\"22045853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The CC' loop of the Act1 SEFIR domain (not the BB' loop as in TIR domains) is required for heterotypic interaction with IL-17RA SEFIR domain. Deletion of the CC' loop from Act1 or IL-17RA abolished the Act1-IL-17RA interaction. Surface plasmon resonance confirmed direct binding of a CC' loop peptide to IL-17RA. A cell-permeable CC' loop decoy peptide inhibited IL-17- and IL-25-mediated signaling in vitro and in vivo.\",\n      \"method\": \"Co-immunoprecipitation, SEFIR domain deletion mutagenesis, surface plasmon resonance, cell-permeable peptide inhibition in vitro and in vivo\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct binding measured by SPR, mutagenesis of both interacting proteins, and in vivo validation with decoy peptide\",\n      \"pmids\": [\"22045852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Act1 is recruited to CD40 and BAFFR indirectly via TRAF3 through a TRAF-binding site in Act1, whereas Act1 interacts with IL-17R through its C-terminal SEFIR domain. These distinct domain requirements underlie the opposing roles of Act1 in B cell vs. T cell signaling.\",\n      \"method\": \"Domain interaction analysis, genetic knockout, double-knockout epistasis\",\n      \"journal\": \"Cytokine / Advances in experimental medicine and biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain-level interactions established by Co-IP and genetic approaches, reviewed/consolidated evidence\",\n      \"pmids\": [\"18061473\", \"21948371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Act1 is a client protein of the molecular chaperone Hsp90. The psoriasis-associated D10N variant of Act1 is defective in its interaction with Hsp90, resulting in global loss of Act1 function. Act1-deficient mice develop spontaneous IL-22-dependent skin inflammation, revealing that loss of Act1 function in IL-17 signaling leads to hyperactive Th17 responses.\",\n      \"method\": \"Co-immunoprecipitation of Act1-Hsp90, Act1-deficient mice, conditional knockout, cytokine/antibody neutralization in vivo\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP, genetic KO, in vivo disease model, and mechanistic connection to psoriasis variant, multiple orthogonal methods\",\n      \"pmids\": [\"23202271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TBK1 directly phosphorylates Act1 on three serine sites to suppress IL-17R-mediated NF-κB activation. IKKi also phosphorylates Act1 on the same sites redundantly. Phosphorylation of these sites inhibits Act1 association with TRAF6 and consequently NF-κB activation. TRAF6 (not TRAF3) is critical for IL-17-induced TBK1 activation, its association with Act1, and subsequent Act1 phosphorylation.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis, co-immunoprecipitation, siRNA knockdown, immunoblot for phosphorylation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay with site mutagenesis combined with co-IP and genetic knockdown to place TBK1 in the pathway\",\n      \"pmids\": [\"22851696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Act1 mediates IL-17-induced EAE pathogenesis selectively in NG2+ glial cells, not in neurons or mature oligodendrocytes. Deletion of Act1 in NG2+ glia resulted in markedly reduced EAE severity. IL-17 exhibited inhibitory effects on maturation and survival of oligodendrocyte lineage cells.\",\n      \"method\": \"Conditional cell-type-specific Act1 knockout mice (NG2-Cre, GFAP-Cre, Olig1-Cre, Syn1-Cre), EAE model, in vitro oligodendrocyte differentiation assays\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple conditional KO lines with defined cellular specificity and in vivo phenotype\",\n      \"pmids\": [\"23995070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A biallelic missense mutation (T536I) in ACT1, located in the SEFIR domain, abolished the homotypic interaction of ACT1 with IL-17 receptors (but not homodimerization), resulting in failure to respond to IL-17A, IL-17F, and IL-17E in patient fibroblasts and T cells. In contrast, the D10N variant in the TRAF-interacting domain impairs but does not abolish IL-17 responses.\",\n      \"method\": \"Patient-derived fibroblasts, Co-IP of mutant ACT1 with IL-17R, cytokine response assays, comparison of SEFIR vs. TRAF-domain mutations\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — natural human mutation with loss-of-function validated in patient cells with mechanistic domain localization confirmed by Co-IP\",\n      \"pmids\": [\"24120361\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HuR is required for IL-17-induced Act1-mediated CXCL1/CXCL5 mRNA stabilization. Act1-mediated polyubiquitination of HuR is required for HuR binding to CXCL1 mRNA, leading to mRNA stabilization. IL-17 induces co-shift of Act1 and HuR to polysomal fractions; HuR deficiency reduces translation-active chemokine mRNAs.\",\n      \"method\": \"HuR knockout in distal lung epithelium, Co-IP of Act1-HuR, sucrose gradient fractionation, mRNA decay assay, in vivo neutrophilia model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO combined with biochemical Co-IP and polysome profiling, in vivo validation\",\n      \"pmids\": [\"23772036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Chlamydia pneumoniae inclusion membrane protein CP0236 interacts with Act1 in HeLa cells. C. pneumoniae infection causes Act1 to associate with the chlamydial inclusion membrane, sequestering it away from the IL-17 receptor, thereby inhibiting NF-κB activation in IL-17-stimulated infected cells.\",\n      \"method\": \"Yeast two-hybrid screen, co-immunoprecipitation of CP0236 with endogenous Act1, immunofluorescence localization\",\n      \"journal\": \"Cellular microbiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid confirmed by co-IP, localization study with functional consequence, single lab\",\n      \"pmids\": [\"19159390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The crystal structure of the IL-17RA SEFIR domain at 2.3 Å resolution reveals that helix αC is critical for interaction with Act1 and IL-17-stimulated gene expression. The CC' loop region and helix αC form a composite ligand-binding surface for recruiting Act1, defining the structural basis for SEFIR-SEFIR interaction specificity.\",\n      \"method\": \"X-ray crystallography (2.3 Å resolution), structure-based mutagenesis, gene expression assays\",\n      \"journal\": \"Acta crystallographica. Section D, Biological crystallography\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with functional validation by mutagenesis of critical interaction helix\",\n      \"pmids\": [\"24816115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The psoriasis-associated D10N variant of ACT1 shows reduced binding to TRAF6, suggesting altered modulation of immunoregulatory signals through TRAF interactions. Functional assays demonstrated this impaired binding is associated with reduced IL-17 signaling activity.\",\n      \"method\": \"Functional binding assay, variant protein expression, comparison of wild-type vs. D10N variant interaction with TRAF6\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional binding assay with disease-associated variant, replicated in subsequent studies\",\n      \"pmids\": [\"20953186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Syk kinase is recruited to the IL-17R signaling complex (with TRAF6 and Act1) upon IL-17A stimulation. Syk acts upstream of TAK1. Syk siRNA or pharmacological inhibition diminished TRAF6-Act1 interaction and TRAF6 K63-polyubiquitination, placing Syk as an upstream regulator of Act1-TRAF6 interaction in IL-17 signaling.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, kinase inhibitor, TRAF6 ubiquitination assay, CCL20 promoter activity\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and siRNA with functional ubiquitination readout, single lab\",\n      \"pmids\": [\"25202827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ACT1 has two human isoforms (D10N and D19N) due to alternative splicing. Both are Hsp90 client proteins, but ACT1-D19N has an additional 9 amino acids providing a second Hsp90 binding site absent in ACT1-D10N. ACT1-D10N is a non-functional dead protein for IL-17 signaling, whereas ACT1-D19N is fully responsive. The two isoforms are differentially expressed in fibroblasts vs. T cells.\",\n      \"method\": \"Hsp90 co-IP with isoform-specific constructs, IL-17 signaling functional assay, isoform expression analysis in primary cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP domain mapping with functional assays in primary cells, single lab\",\n      \"pmids\": [\"25024377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IL-17-induced CIKS/Act1 interaction with the DEAD box protein DDX3X (requiring the DDX3X helicase domain but not its ATPase activity) controls the stability of Zc3h12a mRNA. DDX3X knockdown decreases IL-17-induced Zc3h12a mRNA stability without affecting other mRNAs. IKKε, TRAF2, and TRAF5 are also required for this stabilization.\",\n      \"method\": \"Co-immunoprecipitation of CIKS-DDX3X, DDX3X knockdown, mRNA stability assay, RIP (RNA immunoprecipitation)\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain requirement and RNA-binding confirmation, single lab\",\n      \"pmids\": [\"25710910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Act1 binds and stabilizes mRNAs encoding key inflammatory proteins via its SEFIR domain binding to a stem-loop structure (SEFIR-binding element, SBE) in the 3' UTR of Cxcl1 mRNA. mRNA-bound Act1 directs formation of three compartmentally distinct RNA-protein complexes (RNPs) that regulate: (1) preventing mRNA decay in the nucleus, (2) inhibiting mRNA decapping in P-bodies, and (3) promoting translation. SBE RNA aptamers decreased IL-17-mediated mRNA stabilization and inflammation in vivo.\",\n      \"method\": \"RNA immunoprecipitation, SEFIR domain mutagenesis, sucrose gradient polysome fractionation, P-body imaging, SBE aptamer inhibition in vitro and in vivo mouse models\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal biochemical methods (RIP, RNA structure, polysome profiling, P-body imaging) plus in vivo therapeutic validation with aptamers\",\n      \"pmids\": [\"29563620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Act1 functions as a negative regulator in T and B cells via direct inhibition of STAT3. Mass spectrometry identified an Act1-STAT3 complex. Act1 deficiency (but not IL-17RA/RC/RB deficiency) results in hyperactivated IL-23- and IL-21-induced STAT3 activation in T and B cells, respectively, causing SLE- and Sjögren's-like diseases.\",\n      \"method\": \"Mass spectrometry identification of Act1-STAT3 complex, co-immunoprecipitation, conditional KO comparison (Act1 vs. IL-17R subunits), STAT3 phosphorylation assay, in vivo disease model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — MS identification of complex confirmed by Co-IP, genetic comparison of multiple KO lines defines STAT3 as Act1-specific target independent of IL-17R\",\n      \"pmids\": [\"30013031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The FYN-TRAF3IP2 gene fusion (identified in peripheral T-cell lymphoma) leads to aberrant NF-κB signaling downstream of T cell receptor activation. FYN-TRAF3IP2 expression in hematopoietic progenitors induces NF-κB-driven T cell transformation in mice and cooperates with Tet2 loss. IκB kinase inhibitors delivered anti-lymphoma effects in vitro and in vivo.\",\n      \"method\": \"RNA-sequencing identification of fusion, mouse hematopoietic progenitor transformation assay, NF-κB signaling analysis, IKK inhibitor treatment in vitro and in vivo\",\n      \"journal\": \"Nature cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo transformation assay with genetic epistasis (Tet2 cooperation) and pharmacological validation with IKK inhibitors, replicated in independent cohort\",\n      \"pmids\": [\"33928261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CIKS/Act1 binds to IKK and JNK under basal conditions (functioning as a scaffold), and this association is enhanced by Angiotensin-II stimulation. CIKS-null cardiomyocytes lack Ang-II-induced IKK/NF-κB and JNK/AP-1 activation, IL-18 and MMP-9 induction, and hypertrophy both in vitro and in vivo, demonstrating CIKS is required for Ang-II-induced cardiac hypertrophy.\",\n      \"method\": \"Co-immunoprecipitation (CIKS/IKK/JNK), CIKS-null mice, Ang-II infusion model, cardiac function measurements\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP scaffold function and genetic KO with in vivo disease model, single lab\",\n      \"pmids\": [\"22575763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"IL-17A stimulates the recruitment of MST1 to ACT1 in keratinocytes, which leads to reduced MST1-LATS1 interaction and YAP dephosphorylation (activation), promoting AREG expression and keratinocyte proliferation.\",\n      \"method\": \"Co-immunoprecipitation of ACT1-MST1, YAP phosphorylation immunoblot, keratinocyte proliferation assay\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and downstream phosphorylation assays establishing a new ACT1-MST1-YAP axis, single lab\",\n      \"pmids\": [\"35304250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"A novel amino-terminal motif of Act1 is critical for binding to TRAF6 and activating NF-κB-dependent gene expression, conserved throughout vertebrate evolution. Zebrafish Act1 (lacking the helix-loop-helix and Ufd2-box domains present in higher vertebrates) cannot induce JNK phosphorylation or activate cytokine expression in human cells, but can still bind TRAF6 and activate NF-κB.\",\n      \"method\": \"Evolutionary sequence analysis, domain truncation, co-immunoprecipitation of zebrafish Act1 with human TRAF6, NF-κB reporter assay, JNK phosphorylation assay\",\n      \"journal\": \"Journal of molecular evolution\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain functional analysis using orthologs with co-IP and reporter assays, single lab\",\n      \"pmids\": [\"21643828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Diabetes-induced retinal endothelial cell death occurs through an IL-17A/IL-17R → Act1/FADD signaling cascade causing caspase-mediated apoptosis. Act1 was shown to interact with FADD, identifying Act1 as a bridge between the IL-17 receptor complex and the apoptotic FADD/caspase pathway.\",\n      \"method\": \"IL-17A-/- mouse STZ diabetes model, retinal endothelial cell ex vivo studies, Act1/FADD signaling pathway analysis, capillary degeneration quantification\",\n      \"journal\": \"Journal of diabetes and its complications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO model with ex vivo mechanistic pathway tracing, single lab\",\n      \"pmids\": [\"31239234\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TRAF3IP2/Act1 is a multifunctional cytoplasmic adaptor and U-box E3 ubiquitin ligase that serves as the essential membrane-proximal signal transducer for the IL-17 receptor family: upon IL-17 stimulation, Act1 is recruited to IL-17RA via heterotypic CC'-loop-mediated SEFIR domain interaction, where it catalyzes Lys63-linked ubiquitination of TRAF6 (via Ubc13-Uev1A) to activate IKK/NF-κB and JNK/AP-1, stabilizes inflammatory mRNAs by binding SEFIR-binding elements in their 3'-UTRs to assemble nucleus/P-body/polysome RNP complexes, and can be negatively regulated by TBK1/IKKi-mediated phosphorylation that disrupts Act1-TRAF6 interaction or by SCFβ-TrCP-mediated Lys48-linked degradation; independently of IL-17 signaling, Act1 acts as a negative regulator in B cells (attenuating CD40/BAFF-mediated survival via TRAF3) and in T/B cells (directly inhibiting STAT3), and the oncogenic FYN-TRAF3IP2 fusion drives NF-κB-dependent T cell lymphoma downstream of TCR activation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TRAF3IP2 (Act1/CIKS) is the essential membrane-proximal adaptor and signal transducer of the IL-17 receptor family, coupling IL-17/IL-25 receptor engagement to inflammatory gene expression in fibroblasts, epithelial cells, astrocytes, and CNS glia [#6, #7, #10, #11, #18]. Upon IL-17 stimulation, Act1 is recruited to IL-17RA through a heterotypic SEFIR-SEFIR interaction in which the Act1 CC' loop engages a composite surface formed by the IL-17RA CC' loop and helix \\u03b1C [#14, #22], and it then recruits TRAF6 and TAK1 to activate IKK/NF-\\u03baB and JNK/AP-1 [#1, #2, #7]. Act1 itself is a U-box E3 ubiquitin ligase that, with the Ubc13-Uev1A E2, catalyzes Lys63-linked ubiquitination of TRAF6 at Lys-124, an activity required for downstream NF-\\u03baB signaling [#9]. Beyond transcriptional activation, Act1 binds a SEFIR-binding element stem-loop in the 3'-UTR of inflammatory mRNAs (e.g., Cxcl1) to assemble compartmentally distinct nuclear, P-body, and polysomal RNP complexes that prevent decay, block decapping, and promote translation, in part through ubiquitination of HuR and interaction with DDX3X [#20, #26, #27]. Act1 signaling is constrained by TBK1/IKKi-mediated phosphorylation that disrupts Act1-TRAF6 binding and by SCF\\u03b2-TrCP-mediated Lys48 ubiquitination and degradation [#13, #17], and its folding and function depend on the chaperone Hsp90 [#16]. Independently of IL-17 signaling, Act1 acts as a negative regulator: it attenuates CD40/BAFF-driven B cell survival via a TRAF3-dependent interaction [#3, #5, #15] and directly inhibits STAT3 in T and B cells [#28]. Human SEFIR-domain (T536I) and TRAF-domain (D10N) variants cause loss or impairment of IL-17 responsiveness and underlie chronic mucocutaneous candidiasis-type immunodeficiency and psoriasis susceptibility [#19, #16, #23], while the oncogenic FYN-TRAF3IP2 fusion drives NF-\\u03baB-dependent peripheral T-cell lymphoma downstream of TCR activation [#29].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established Act1/CIKS as a NEMO-binding activator of the IKK\\u2013NF-\\u03baB and JNK cascades, defining it as a signaling adaptor rather than an enzyme of unknown role.\",\n      \"evidence\": \"Reciprocal co-IP with NEMO, ectopic expression, NF-\\u03baB reporter and JNK assays with dominant-negative IKK in mammalian cells\",\n      \"pmids\": [\"10962033\", \"10962024\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The upstream receptor was unidentified; the IL-1-unresponsive cell line implicated an unknown component\", \"No endogenous-level mechanism or substrate defined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Placed TRAF6 immediately downstream of Act1 and showed Act1 engages CD40 receptor signaling, beginning to map the adaptor into specific receptor pathways.\",\n      \"evidence\": \"Co-IP with domain mapping, dominant-negative TRAF6 epistasis, and endogenous CD40 recruitment with rescue in epithelial cells\",\n      \"pmids\": [\"12459498\", \"12089335\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"TRAF6 selectivity established but biochemical mechanism of activation unknown\", \"CD40 vs IL-1 pathway distinction not yet resolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Revealed a context-dependent dual function: Act1 is a negative regulator of CD40/BAFF-mediated B cell survival, contrasting its activating role elsewhere.\",\n      \"evidence\": \"Genetic knockout with CD40-Act1 and BAFF-Act1 double-knockout epistasis and multi-pathway signaling immunoblots in B cells\",\n      \"pmids\": [\"15485634\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for the inhibitory (vs activating) outcome not defined\", \"Domain requirements distinguishing the two roles unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified Act1 as the essential, non-redundant adaptor for IL-17 (and later IL-25) receptor signaling in vivo via SEFIR-domain recruitment, defining its principal physiological pathway.\",\n      \"evidence\": \"Genetic KO mice, primary astroglial/epithelial cells, co-IP defining the IL-17R\\u2013Act1\\u2013TRAF6\\u2013TAK1 complex, EAE and colitis disease models\",\n      \"pmids\": [\"17277779\", \"17035243\", \"19155512\", \"19155511\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of SEFIR-SEFIR specificity not yet resolved\", \"Whether Act1 acts catalytically or only as scaffold unresolved at this stage\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrated Act1 is itself a U-box E3 ligase that K63-ubiquitinates TRAF6 at K124, converting it from a passive scaffold to an active enzyme essential for IL-17-driven NF-\\u03baB.\",\n      \"evidence\": \"In vitro ubiquitination reconstitution with Ubc13-Uev1A, U-box and TRAF6-K124 mutagenesis, rescue of Act1-/- MEFs\",\n      \"pmids\": [\"19825828\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether all Act1 functions require ligase activity not established\", \"Regulation of the ligase activity in vivo undefined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined the structural and regulatory logic of the IL-17R interaction and its negative control, including CC'-loop SEFIR binding and \\u03b2-TrCP-mediated degradation.\",\n      \"evidence\": \"SPR binding of CC' loop peptide, mutagenesis of both partners, decoy-peptide inhibition in vivo, and co-IP/siRNA mapping of SCF\\u03b2-TrCP degradation\",\n      \"pmids\": [\"22045852\", \"22045853\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase generating the phosphodegron not identified in this work\", \"Stoichiometry of degradative vs signaling pools unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Resolved how Act1 stability and signaling are gated by Hsp90 chaperoning and by TBK1/IKKi phosphorylation that uncouples Act1 from TRAF6, and linked the D10N variant to psoriasis.\",\n      \"evidence\": \"Co-IP of Act1-Hsp90 and Act1-TBK1, in vitro kinase assay with site mutagenesis, conditional KO mice and in vivo cytokine neutralization\",\n      \"pmids\": [\"23202271\", \"22851696\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How phosphorylation and degradation feedback are temporally coordinated unclear\", \"Hsp90 client maturation steps not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established Act1 as a post-transcriptional regulator that stabilizes inflammatory mRNAs via HuR, and confirmed human disease causation through the SEFIR-domain T536I mutation.\",\n      \"evidence\": \"HuR KO, Act1-HuR co-IP, polysome fractionation, mRNA decay assays; patient-derived fibroblasts/T cells with co-IP of mutant ACT1\",\n      \"pmids\": [\"23772036\", \"24120361\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct RNA-binding element on target mRNAs not yet mapped\", \"Genotype\\u2013phenotype distinction between SEFIR and TRAF-domain mutations only partially defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Extended the RNA-regulatory mechanism by showing Act1 partners with DDX3X (and TRAF2/TRAF5/IKK\\u03b5) to selectively stabilize specific transcripts such as Zc3h12a.\",\n      \"evidence\": \"Co-IP of CIKS-DDX3X with helicase-domain requirement, DDX3X knockdown, RIP and mRNA stability assays\",\n      \"pmids\": [\"25710910\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; transcript selectivity mechanism incompletely defined\", \"Relationship between DDX3X and HuR pathways not integrated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Unified the RNA function into a structural model where Act1 binds a 3'-UTR SEFIR-binding element to assemble compartment-specific RNPs, and revealed a separable IL-17-independent role inhibiting STAT3.\",\n      \"evidence\": \"RIP, RNA structure mapping, polysome profiling, P-body imaging, aptamer therapy in vivo; mass spectrometry of Act1-STAT3 with comparative KO mice\",\n      \"pmids\": [\"29563620\", \"30013031\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Act1 distributes between cytoplasmic signaling, RNP, and nuclear STAT3-inhibitory pools is unresolved\", \"Mechanism of direct STAT3 inhibition not biochemically defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed that genomic fusion of TRAF3IP2 to FYN constitutively drives NF-\\u03baB signaling and T-cell transformation, establishing an oncogenic gain-of-function for the adaptor.\",\n      \"evidence\": \"RNA-seq fusion identification, mouse hematopoietic progenitor transformation, Tet2-loss cooperation, IKK inhibitor treatment in vitro and in vivo\",\n      \"pmids\": [\"33928261\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which the FYN moiety activates Act1-NF-\\u03baB output not fully defined\", \"Whether endogenous Act1 enzymatic functions are required for transformation unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single adaptor is partitioned among its activating (IL-17R/TRAF6/NF-\\u03baB), post-transcriptional (RNP/HuR/DDX3X), and inhibitory (CD40/BAFF, STAT3) functions, and how its phosphorylation, ubiquitination, and chaperoning are integrated to dictate these outcomes, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model of Act1 pool partitioning across compartments\", \"Regulatory hierarchy linking TBK1 phosphorylation, \\u03b2-TrCP degradation, and Hsp90 chaperoning not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [6, 7, 14]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1, 2, 7]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [20, 27]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 1, 6, 7]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [27]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6, 7, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 7, 10, 28]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 7, 9]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [20, 26, 27]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [16, 19, 29]}\n    ],\n    \"complexes\": [\"IL-17 receptor signaling complex (IL-17RA\\u2013Act1\\u2013TRAF6\\u2013TAK1)\", \"SCF\\u03b2-TrCP E3 ligase complex (substrate)\"],\n    \"partners\": [\"IL17RA\", \"TRAF6\", \"NEMO/IKBKG\", \"TRAF3\", \"HuR/ELAVL1\", \"DDX3X\", \"STAT3\", \"HSP90\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}